347 related articles for article (PubMed ID: 32438972)
1. Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer.
Lim D; Do Y; Kwon BS; Chang W; Lee MS; Kim J; Cho JG
BMB Rep; 2020 Jun; 53(6):291-298. PubMed ID: 32438972
[TBL] [Abstract][Full Text] [Related]
2. cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer.
Wang Y; Tong L; Wang J; Luo J; Tang J; Zhong L; Xiao Q; Niu W; Li J; Zhu J; Chen H; Li X; Wang Y
Acta Biomater; 2019 Aug; 94():495-504. PubMed ID: 31252171
[TBL] [Abstract][Full Text] [Related]
3. Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma.
Zheng N; Zhang S; Wu W; Zhang N; Wang J
Pharmacol Res; 2021 Apr; 166():105507. PubMed ID: 33610718
[TBL] [Abstract][Full Text] [Related]
4. cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer.
Tang J; Wang J; Fan L; Li X; Liu N; Luo W; Wang J; Wang Y; Wang Y
Oncotarget; 2016 Apr; 7(17):24050-62. PubMed ID: 26992227
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of compound DMBT on hypoxia-induced vasculogenic mimicry in human breast cancer.
Li S; Zhang Q; Zhou L; Guan Y; Chen S; Zhang Y; Han X
Biomed Pharmacother; 2017 Dec; 96():982-992. PubMed ID: 29208325
[TBL] [Abstract][Full Text] [Related]
6. Vasculogenic mimicry in carcinogenesis and clinical applications.
Luo Q; Wang J; Zhao W; Peng Z; Liu X; Li B; Zhang H; Shan B; Zhang C; Duan C
J Hematol Oncol; 2020 Mar; 13(1):19. PubMed ID: 32169087
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Vasculogenic Mimicry in Ovarian Cancer.
Ayala-Domínguez L; Olmedo-Nieva L; Muñoz-Bello JO; Contreras-Paredes A; Manzo-Merino J; Martínez-Ramírez I; Lizano M
Front Oncol; 2019; 9():998. PubMed ID: 31612116
[TBL] [Abstract][Full Text] [Related]
8. Signaling pathways in tumor vasculogenic mimicry.
Vartanian AA
Biochemistry (Mosc); 2012 Sep; 77(9):1044-55. PubMed ID: 23157265
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs.
Hu H; Ma T; Liu N; Hong H; Yu L; Lyu D; Meng X; Wang B; Jiang X
Int Immunopharmacol; 2022 Oct; 111():109116. PubMed ID: 35969899
[TBL] [Abstract][Full Text] [Related]
10. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
11. Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry.
Wang JY; Sun T; Zhao XL; Zhang SW; Zhang DF; Gu Q; Wang XH; Zhao N; Qie S; Sun BC
Cancer Biol Ther; 2008 May; 7(5):758-66. PubMed ID: 18376140
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system.
Qu B; Guo L; Ma J; Lv Y
Med Hypotheses; 2010 Feb; 74(2):360-1. PubMed ID: 19744799
[TBL] [Abstract][Full Text] [Related]
13. Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes.
Han H; Du L; Cao Z; Zhang B; Zhou Q
Eur J Pharmacol; 2018 Jan; 818():593-603. PubMed ID: 29162433
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.
Wei X; Chen Y; Jiang X; Peng M; Liu Y; Mo Y; Ren D; Hua Y; Yu B; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Xiong W; Zeng Z
Mol Cancer; 2021 Jan; 20(1):7. PubMed ID: 33397409
[TBL] [Abstract][Full Text] [Related]
15. The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer.
Sun Q; Zou X; Zhang T; Shen J; Yin Y; Xiang J
Gynecol Oncol; 2014 Mar; 132(3):730-8. PubMed ID: 24503464
[TBL] [Abstract][Full Text] [Related]
16. Targeting vasculogenic mimicry by phytochemicals: A potential opportunity for cancer therapy.
Haiaty S; Rashidi MR; Akbarzadeh M; Maroufi NF; Yousefi B; Nouri M
IUBMB Life; 2020 May; 72(5):825-841. PubMed ID: 32026601
[TBL] [Abstract][Full Text] [Related]
17. The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment.
Li S; Meng W; Guan Z; Guo Y; Han X
Biomed Pharmacother; 2016 May; 80():127-135. PubMed ID: 27133049
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor/heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem/progenitor cells.
Lee CH; Wu YT; Hsieh HC; Yu Y; Yu AL; Chang WW
Biochimie; 2014 Sep; 104():117-26. PubMed ID: 24950183
[TBL] [Abstract][Full Text] [Related]
19. Epithelial-to-endothelial transition and cancer stem cells: two cornerstones of vasculogenic mimicry in malignant tumors.
Sun B; Zhang D; Zhao N; Zhao X
Oncotarget; 2017 May; 8(18):30502-30510. PubMed ID: 27034014
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
